1
|
Su L, Song G, Zhou T, Tian H, Xin H, Zou X, Xu Y, Jin X, Gui S, Lu X. Colon-targeted oral nanoliposomes loaded with psoralen alleviate DSS-induced ulcerative colitis. Biomater Sci 2024. [PMID: 38757193 DOI: 10.1039/d4bm00321g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/18/2024]
Abstract
Oral administration, while convenient, but complex often faces challenges due to the complexity of the digestive environment. In this study, we developed a nanoliposome (NLP) encapsulating psoralen (P) and coated it with chitosan (CH) and pectin (PT) to formulate PT/CH-P-NLPs. PT/CH-P-NLPs exhibit good biocompatibility, superior to liposomes loaded with psoralen and free psoralen alone. After oral administration, PT/CH-P-NLPs remain stable in the stomach and small intestine, followed by a burst release of psoralen after reaching the slightly alkaline and gut microbiota-rich colon segment. In the DSS-induced ulcerative colitis of mice, PT/CH-P-NLPs showed significant effects on reducing inflammation, mitigating oxidative stress, protecting the integrity of the colon mucosal barrier, and modulating the gut microbiota. In conclusion, the designed nanoliposomes demonstrated the effective application of psoralen in treating ulcerative colitis.
Collapse
Affiliation(s)
- Liqian Su
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of BasicMedical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, People's Republic of China.
| | - Gaoqing Song
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of BasicMedical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, People's Republic of China.
- Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, People's Republic of China
- Intensive Care Unit, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen 518031, People's Republic of China
| | - Tao Zhou
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of BasicMedical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, People's Republic of China.
- Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, People's Republic of China
- Intensive Care Unit, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen 518031, People's Republic of China
| | - Hongmei Tian
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of BasicMedical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, People's Republic of China.
- Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, People's Republic of China
- Intensive Care Unit, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen 518031, People's Republic of China
| | - Hui Xin
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of BasicMedical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, People's Republic of China.
- Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, People's Republic of China
- Intensive Care Unit, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen 518031, People's Republic of China
| | - Xuan Zou
- Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, People's Republic of China
| | - Yinghua Xu
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotechnology Products, National Institutes for Food and Drug Control, Beijing 102629, People's Republic of China
| | - Xiaobao Jin
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of BasicMedical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, People's Republic of China.
| | - Shuiqing Gui
- Intensive Care Unit, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen 518031, People's Republic of China
| | - Xuemei Lu
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of BasicMedical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, People's Republic of China.
- Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, People's Republic of China
| |
Collapse
|
2
|
Kobets T, Smith BPC, Williams GM. Food-Borne Chemical Carcinogens and the Evidence for Human Cancer Risk. Foods 2022; 11:foods11182828. [PMID: 36140952 PMCID: PMC9497933 DOI: 10.3390/foods11182828] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 09/07/2022] [Accepted: 09/08/2022] [Indexed: 11/16/2022] Open
Abstract
Commonly consumed foods and beverages can contain chemicals with reported carcinogenic activity in rodent models. Moreover, exposures to some of these substances have been associated with increased cancer risks in humans. Food-borne carcinogens span a range of chemical classes and can arise from natural or anthropogenic sources, as well as form endogenously. Important considerations include the mechanism(s) of action (MoA), their relevance to human biology, and the level of exposure in diet. The MoAs of carcinogens have been classified as either DNA-reactive (genotoxic), involving covalent reaction with nuclear DNA, or epigenetic, involving molecular and cellular effects other than DNA reactivity. Carcinogens are generally present in food at low levels, resulting in low daily intakes, although there are some exceptions. Carcinogens of the DNA-reactive type produce effects at lower dosages than epigenetic carcinogens. Several food-related DNA-reactive carcinogens, including aflatoxins, aristolochic acid, benzene, benzo[a]pyrene and ethylene oxide, are recognized by the International Agency for Research on Cancer (IARC) as causes of human cancer. Of the epigenetic type, the only carcinogen considered to be associated with increased cancer in humans, although not from low-level food exposure, is dioxin (TCDD). Thus, DNA-reactive carcinogens in food represent a much greater risk than epigenetic carcinogens.
Collapse
Affiliation(s)
- Tetyana Kobets
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
- Correspondence: ; Tel.: +1-914-594-3105; Fax: +1-914-594-4163
| | - Benjamin P. C. Smith
- Future Ready Food Safety Hub, Nanyang Technological University, Singapore 639798, Singapore
| | - Gary M. Williams
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
| |
Collapse
|
3
|
Abstract
Assessment of short-term and long-term effects of light (pho—totesting) is part of the safety evaluation of drugs. Results are incorporated into drug package inserts to advise patients and health care providers about the use of drug products on sun—exposed skin. We undertook an exhaustive literature search and a search of archived studies at the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), in order to evaluate the potential of short—term photoassays to predict long—term effects of drugs used in sunlight (280–700 nm). The correlation between the findings from the photococarcinogenicity assays in mice that used exposure to simulated sunlight and those from photogenotoxicity and photosensitivity studies was examined. Results indicated that photosensitivity and photogenotoxicity assays did not necessarily predict effects in photococarcinogenicity studies in mice. Effects of drugs on skin that are not due to photoactivation of drug can be important factors in enhancement of UV—induced skin carcinogenesis.
Collapse
Affiliation(s)
- Abigail Jacobs
- Division of Dermatologic and Dental Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD, USA
| | - Javier Avalos
- Division of Dermatologic and Dental Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD, USA
| | - Paul Brown
- Division of Dermatologic and Dental Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD, USA
| | - Jonathan Wilkin
- Division of Dermatologic and Dental Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD, USA
| |
Collapse
|